A longitudinal seroconversion panel shows anti-SARS-CoV-2 antibody levels up to 6.5 months after vaccination with mRNA-1273 (Moderna)
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Background
Vaccines have emerged as a crucial tool in combatting the COVID-19 pandemic particularly those based on SARS-CoV-2 S-protein mRNA. A crucial aspect of vaccine efficacy is the duration of antibody responses. In this study, a seroconversion panel was created to assess antibody responses to the mRNA-1273 vaccine over time (6.5 months).
Methods
Blood samples collected from 15 healthy adult participants prior to and up to 6.5 months after vaccination with the mRNA-1273 vaccine (Moderna). Serum from these blood samples were analyzed for anti-SARS-CoV-2 antibody activity by chemiluminescent immunoassay.
Results
The immunoassay results showed that one participant was positive for anti-SARS-CoV- 2 antibodies prior to vaccination indicating a prior infection. All participants showed a positive antibody response after the first vaccination. Highest antibody responses were seen after the second dose (41-45 days from the first dose). Subsequent samples collected at 69-75 days, 130-135 days and 221-229 days after the first vaccination showed positive responses but declining levels of anti-SARS-CoV-2 antibodies.
Conclusions
Declining antibody levels in these participants support the use of booster vaccination to increase antibody levels 4-6 months after the initial vaccine series and continued monitoring to assess the durability of COVID-19 vaccine responses. These results are in agreement with other studies showing antibody persistence but declining the antibody levels in the months after immunization with mRNA-based vaccines.
Article activity feed
-
SciScore for 10.1101/2022.01.25.22269762: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Seroconversion panel collection: The samples which make up these seroconversion panels were collected from volunteer healthcare workers at a Morristown, Tennessee (USA) hospital that had provided informed consent.
IRB: This study was conducted under an approved IRB protocol ([SDP-003] Human Biological Specimen Collections: Diagnostic Investigational Review Board, Cummaquid, MA, USA).Sex as a biological variable There were nine male and six female participants in this group. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources The serum samples were tested for anti-SARS-CoV-2 antibody activity with a chemiluminescent … SciScore for 10.1101/2022.01.25.22269762: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Seroconversion panel collection: The samples which make up these seroconversion panels were collected from volunteer healthcare workers at a Morristown, Tennessee (USA) hospital that had provided informed consent.
IRB: This study was conducted under an approved IRB protocol ([SDP-003] Human Biological Specimen Collections: Diagnostic Investigational Review Board, Cummaquid, MA, USA).Sex as a biological variable There were nine male and six female participants in this group. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources The serum samples were tested for anti-SARS-CoV-2 antibody activity with a chemiluminescent immunoassay (CLIA: Liaison SARS-CoV-2 IgG Assay, Diasorin, Inc, Saluggia, Italy: EUA approved). anti-SARS-CoV-2suggested: NoneSoftware and Algorithms Sentences Resources This study was conducted under an approved IRB protocol ([SDP-003] Human Biological Specimen Collections: Diagnostic Investigational Review Board, Cummaquid, MA, USA). Human Biologicalsuggested: ( Human Biological Data Interchange , RRID:SCR_004591)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
-